@Article{,
AUTHOR = {Hriday P. Bhambhvani, Daniel R. Greenberg, Alex M. Kasman, Michael L. Eisenberg},
TITLE = {Primary malignancies of the epididymis: clinical characteristics and prognostic factors},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {28},
YEAR = {2021},
NUMBER = {1},
PAGES = {10522--10529},
URL = {http://www.techscience.com/CJU/v28n1/60230},
ISSN = {1488-5581},
ABSTRACT = {<b>Introduction:</b> We sought to describe clinical characteristics and identify prognostic factors among patients with primary malignancies of the epididymis (PMEs).<br/>
<b>Materials and methods:</b> The Surveillance, Epidemiology, and End Results (SEER) database (1975-2015) was queried to identify patients with PME. Descriptive statistics and multivariable Cox proportional hazards models were used.<br/>
<b>Results:</b> Eighty-nine patients with PME were identified. Median age was 57 years (5-85), and median overall survival (OS) was 16.8 years. The most commonly represented histologies were rhabdomyosarcoma (19.1%), B-cell lymphoma (16.9%), leiomyosarcoma (16.9%), and liposarcoma (12.4%). In multivariable analysis, tumor size ≥ 4 cm was associated with worse OS (HR = 4.46, p = 0.01) compared to tumors < 4 cm. Patients with nonsarcomatoid histology had OS similar to patients with sarcomatoid histology (HR = 0.95, p = 0.92). Disease with regional invasion (HR = 5.19, p = 0.007) and distant metastasis (HR = 29.80, p = 0.0002) had worse OS compared to localized disease. Receipt of radiotherapy was associated with enhanced OS (HR = 0.10, p = 0.006), whereas receipt of chemotherapy was not associated with OS.<br/>
<b>Conclusions:</b> We describe the largest cohort of PMEs to date. Larger lesions and tumor stage were independently associated with poor overall survival, while receipt of radiotherapy was associated with enhanced overall survival.},
DOI = {}
}